Brazil Needs Better Orphan Drug Policies, Says Alexion
Executive Summary
Strengthening Brazil’s policy on orphan drugs would help stem the number of court cases brought by patients to access medicines, says Alexion.
You may also be interested in...
Brazil: Spending On Meds Acquired Through Law Suits Rockets
Brazilian health ministry spending on medicines and treatment supplies acquired by patients taking legal action through the courts has rocketed from R$70m ($22.3) in 2008 to more than R$1bn ($317.9) in 2015, according to an audit by Brazil’s General Accounting Office (TCU).
South American Pricing Coalition Sets Sights On Alexion’s Soliris and Monoclonal Antibodies
A South American pricing coalition that includes Brazil, Venezuela and Argentina has announced plans to buy high-cost drugs, such as eculizumab (Alexion’s Soliris).
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.